Asarina Pharma Scientific Advisory Board gives full backing to Menstrual Migraine Phase IIA trial

Stockholm – December 18, 2018. On December 17 Asarina Pharma’s Scientific Advisory Board (SAB) gave its full backing to the company’s upcoming trial of a new preventive treatment for Menstrual Migraine. The SAB comprises world-leading independent scientists in obstetrics, gynaecology, neurology and pharmacology, including Prof Anne MacGregor, one of the world’s foremost authorities on headache and migraine.

Migraine is more prevalent than diabetes, epilepsy and asthma combined, three times more women than men suffer from it, and 1-in-5 of those suffer from menstrual migraine. Yet currently many therapies treat the symptoms of Menstrual Migraine—but do not prevent it. Sepranolone, the new therapy from Asarina Pharma, aims to prevent Menstrual Migraine from occurring. It targets the exact brain neurosteroid—allopregnanolone—that triggers Menstrual Migraine.

Asarina Pharma’s SAB has now given its input and full backing on the proposed protocol for a Phase IIA clinical study of Sepranolone in Menstrual Migraine, to be initiated before summer 2019.

ALLOPREGNANOLONE—A NEW DISRUPTOR REVEALED. Peter Nordkild, Asarina Pharma CEO: “Our 40 years’ plus of research has tracked down and revealed the massive emotional and behavioural disruption that Allopregnanolone, a single brain neurosteroid, can cause in millions of women’s lives. Our research has shown how our compound Sepranolone dampens the effects of Allopregnanolone. We are confident it could be a powerful, effective preventive treatment for Menstrual Migraine. This trial is an important first step.”

IMPORTANT PRECLINICAL DATA PRESENTED: The SAB was also presented with high-potential pre-clinical data indicating promising results in the treatment of other stress-induced, allopregnanolone-triggered conditions.

WORLD-CLASS SCIENTIFIC ADVISORY BOARD: Asarina Pharma’s Scientific Advisory Board consists of six scientific authorities from the fields of obstetrics, gynaecology, neurology and pharmacology—from the US, UK, Sweden and Germany. It includes:

  • Prof Anne MacGregor, a world class authority on menstrual migraine with over 200 research papers and five books to her name.
  • Asoc Prof Marco Bortolato, a recognised authority on neurodevelopmental disorders and key brain neurotransmitters including conditions impacted by Allopregnanolone such as obsessive compulsive disorder, pathological gambling and Tourette’s.
  • Prof. Dr. h.c. Günther Deuschl is one of the world’s most distinguished Professors of Neurology. He has published over 580 papers and has been president of the European Academy of Neurology.

For further information, please contact:

Peter Nordkild, CEO, Asarina Pharma AB

Phone: +45 25 47 16 46

E-mail: peter.nordkild@asarinapharma.com

About Asarina Pharma AB

We are a Swedish biotech company developing Sepranolone: the world’s first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years’ research into menstrual-related disorders like PMDD, menstrual migraine and menstrual epilepsy. With our new family of GAMSA compounds (GABAA Modulating Steroid Antagonists), we aim to deliver a new generation of safe, targeted treatments for still widely untreated conditions, and to become a leading specialty pharma company in Women’s Health.

Tags:

Subscribe

Documents & Links